Bianca Denise Santomasso MD

PubMed

• Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-t...
  Tessa F Flores, Emily S Tonorezos, Shailender Bhatia, Julie R Brahmer, Laura C Cappelli
  Journal for Immunotherapy of Cancer. 2026-03-03
• 1 citations
  Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.
  Monica F Chen, Jake June-Koo Lee, Noura J Choudhury, Angela B Hui, Mark Y Jeng
  Journal of Thoracic Oncology. 2026-03-01
• 1 citations
  CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.
  Joseph M Rocco, Joseph H Oved, Rikita J Patel, A Zara Herskovits, Namitha Nair
  Blood. 2026-02-26

Abstracts/Posters

• Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Bianca Santomasso, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Neurotoxicity From CAR T-Cell Therapy: Why It Happens, How to Manage It, and Who Is at Risk? 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018